Skip to main content Skip to search Skip to main navigation

EU GMP Guide: Chapter 4, Annex 11 and New Annex 22

The EC has published the long-awaited revised and new documents of the EU GMP Guide for consultation: Chapter 4 Documentation, Annex 11 Computerised Systems and the new Annex 22 Artificial Intelligence. Stakeholder consultations are open until 7 October on the EC website.

Revision of Chapter 4 – Documentation

The updated Chapter 4 emphasises the critical role of documentation in GMP and supports the use of digital, hybrid, and emerging technologies. Risk-based data governance is now a core element to ensure document accuracy, integrity, availability, and legibility across all formats. It also clarifies requirements for managing electronic records, signatures, and data integrity, aligning with the ongoing revision of Annex 11.

Revision of Annex 11 – Computerised Systems

The updated Annex 11 reinforces lifecycle management of computerised systems, requiring comprehensive application of Quality Risk Management. It strengthens requirements for system specifications, supplier oversight, data integrity, audit trails, electronic signatures, and security.

New Annex 22 – Artificial Intelligence

Annex 22 sets out requirements for the use of AI and machine learning in the manufacture of active substances and medicinal products. It covers model selection, training, validation, and performance monitoring. Key areas include intended use, data quality, performance metrics, change control, and human oversight.


Source:

EC: Public Health/Consultations/ Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next